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Abstract
Background: Visceral leishmaniasis is a zoonosis characterized by chronic evolution of symptoms; it usually appears
2 to 4 months after the initial infection, with multiple cutaneous lesions and systemic involvement, which if left
untreated results in death in 90 % of cases.
Case presentation: We present a case of 29-year-old white male farmer, with chronic myeloid leukemia treated
with imatinib who developed significant pancytopenia, leading to discontinuation of treatment. His neutrophil
count fell to 0.5 × 109/L, his platelets dropped to 85 × 109/μL, and his hemoglobin was 6.4 g/dL. A bone marrow
study was performed, showing complete remission of chronic myeloid leukemia and numerous Leishmania
amastigotes within the macrophages. He used pentavalent antimonials replaced by amphotericin B due to acute
cardiac toxicity. After 3 months, imatinib was restarted, and he again showed adequate control of the disease. The
last polymerase chain reaction assessment showed a deep molecular response.
Conclusion: The hypothesis of an adverse event or secondary resistance to tyrosine kinase inhibitors, with
subsequent progression to advanced disease, was initially raised, although a detailed evaluation has shown that it
was an associated infectious disease.
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Background
Chronic myeloid leukemia (CML) is a clonal myelopro-
liferative disorder that results from the malignant trans-
formation of a hematopoietic stem cell. It is
characterized by the Philadelphia chromosome (Ph+),
which is formed by translocation and fusion of the long
arms of chromosomes 9 and 22 in a multipotent
hematopoietic progenitor cell. At the molecular level,
the fusion generates a BCR-ABL protein with constitu-
tive tyrosine kinase activity [1–7]. Tyrosine kinase inhib-
itors (TKIs) such as imatinib are able to suppress the
BCR-ABL+ clone and induce molecular remission [8].
Leishmaniasis is a zoonosis caused by an intracellular
parasite belonging to the genus Leishmania. Leishmania
parasites have a dimorphic life cycle, alternating between
an extracellular promastigote and an intracellular amas-
tigote form [9]. This disease is endemic in 98 countries,
and an estimated 350 million people live in endemic
areas. Despite T-cell-dependent immune responses,
which produce asymptomatic and self-healing infection,
or appropriate treatment, intracellular infection is prob-
ably lifelong because the targeted cells (tissue macro-
phages) allow residual parasites to persist [10].
Case presentation
A 29-year-old white male farmer sought medical atten-
tion because of left upper-quadrant abdominal discom-
fort and unintentional weight loss of 8 kg. His initial
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clinical examination revealed light pallor and spleno-
megaly, 10 cm below his left costal margin. However, no
lymphadenopathy or hepatomegaly was detected. Labora-
tory analysis showed a leukocyte count of 38 × 109/L, a
hemoglobin level of 10.5 g/dL, and a platelet count of
289 × 109/μL. He denied fever or drenching night sweats
and was not taking medication.
He was referred to our Department of Hematology, at
our university hospital, where a bone marrow aspiration
and biopsy were performed. Microscopic examination
showed a left-shifted granulopoiesis, and the Ph + was
found with no other chromosomic aberrations. BCR-ABL
fusion transcript was identified by polymerase chain reac-
tion (PCR) and both transcripts (b2a2 and b3a2) were
present. The diagnosis of CML in chronic phase was
made: Sokal score 0.85 (low risk <0.8; moderate risk 0.8 to
1.2; high risk >1.2) and Hasford score 741 (low risk <780;
moderate risk 780 to 1480; high risk >1480).
He was initially treated with hydroxyurea, which was
later substituted by imatinib 400 mg daily starting in
early January 2013. We observed a slow progression of
the splenomegaly until complete spleen regression by
3 months. The first reevaluation was made at 3 months
of imatinib (early response). During that period he
showed no symptoms and gained weight (4 kg). Early re-
sponse was detected through a cytogenetics analysis and
quantitative polymerase chain reaction (qPCR) assess-
ment. There was no cell growth to perform an analysis
of the Ph + through the G-band method. Fluorescent in
situ hybridization revealed 3.5 % of cells with the gene
fusion, while PCR assessment was not conclusive due to
the low quality of deoxyribonucleic acid (DNA). He was
considered an optimal responder.
He persisted on imatinib 400 mg for 6 months before
the agent was discontinued because of pancytopenia. His
neutrophil count fell to 0.5 × 109/L, platelets dropped to
85 × 109/μL, and hemoglobin was 6.4 g/dL (Fig. 1).
Transfusion was not necessary. After imatinib cessation,
we waited 1 week until a new hemogram was done. Be-
cause there was no improvement in his hemogram we
decided to examine his bone marrow. A bone marrow
study was performed showing complete remission of
CML and numerous Leishmania amastigotes within the
macrophages (Figs. 2 and 3). IgM antibody to Leish-
mania K39 antigen was positive. He was admitted to our
hospital and began treatment with pentavalent antimo-
nials. His hemogram started to improve at 10 days of
leishmaniasis treatment and normalized by 2 months.
New bone marrow aspirate showed no more leishmania-
sis after 60 days of therapy. Complete recovery of symp-
toms and examinations (bone marrow and hemogram)
was seen after that time (Table 1).
Fig. 1 Evolution of patient’s hemogram. The dotted line indicates the nadir counts (when imatinib suspension occurred)
Quixada et al. Journal of Medical Case Reports  (2016) 10:207 Page 2 of 4
Acute cardiac toxicity required suspension from treat-
ment. An electrocardiogram showed prolongation of the
QT interval and bradycardia. The medication was
stopped when his heart rate dropped below 45 beats per
minute; it was replaced by amphotericin B regimen.
After 3 months, TKI therapy was resumed and he again
showed adequate response to imatinib. The last PCR
showed deep molecular response (MR 4.0).
Discussion
Visceral leishmaniasis (VL) is a well-known opportunis-
tic infection in severe immunodeficiency, particularly in
patients living in areas where leishmaniasis is endemic.
In Brazil, VL or neotropical kala-azar, is an endemic/epi-
demic rural and periurban anthropozoonosis with a
strong tendency towards urbanization. It is caused by
different species of the genus Leishmania, and in the
Americas, L. chagasi is the etiological agent of the dis-
ease. The importance of the canine reservoir derives
from the close frequent contact between dogs and
humans and the fact that the animals can present
asymptomatic infection, despite a high degree of parasit-
ism in healthy skin and viscera [11, 12].
We report the case of a farmer diagnosed with CML
who presented with pancytopenia Grade 3/4 during
treatment, which required imatinib suspension. Adher-
ence was good, without the use of any other drugs. Pro-
found involvement of the hematological system in the
form of bone marrow and peripheral blood changes are
consistently seen in VL and include the following.
Normochromic normocytic anemia is a frequent and
clinically significant feature of VL and hemoglobin levels
of 7 to 10 g/dl are commonly found. Leucopenia is an
early and striking manifestation of VL. Platelet counts
are usually affected after long duration of illness. A vary-
ing degree of frequency and severity of pancytopenia has
been reported. In this case we think that both imatinib
treatment and concurrent Leishmania infection played a
role in the cytopenias observed.
The most commonly reported Grade 3 or 4 adverse
events experienced in 5 years of follow-up of newly diag-
nosed patients with CML treated with imatinib as a
first-line therapy were neutropenia, thrombocytopenia,
anemia, and elevated liver enzymes [13]. In our patient,
the diagnosis of leishmaniasis was not anticipated. Pan-
cytopenia was considered an adverse event, and spleen en-
largement after imatinib cessation was attributed to TKI
secondary resistance/progression. Adverse hematologic
side-effects of imatinib include anemia, neutropenia, and
thrombocytopenia. Hematologic toxicity appears mild
to moderate in most instances and is often easily
manageable and potentially reversible. Less than 10 %
of the patients present persistent cytopenias that
might preclude treatment. By the time of imatinib
cessation our concern was about pancytopenia as an
adverse effect. When we stopped imatinib we ob-
served a progressive spleen enlargement. Our patient
had low grade fever and was a farmer. We then ar-
rived at a second diagnostic hypothesis. When a new
evaluation of his bone marrow was performed, the in-
fectious disease was diagnosed.
Fig. 2 Bone marrow aspirate: macrophages containing
Leishman-Donovan bodies
Fig. 3 Bone marrow aspirate: Leishman-Donovan bodies
outside macrophages
Table 1 Clinical and laboratory findings in the patient during
leishmaniasis diagnosis and therapy
Before During treatment After
Hemoglobin (g/dL) 6.4 9.5 12.6
Neutrophil (×109/L) 0.5 1.7 2
Platelet (×109/μL) 85 150 145
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Conclusions
To the best of our knowledge, this report highlights the
importance of careful management of patients with
CML during treatment, with the formulation of different
hypotheses on common situations in an attempt to in-
crease the chance of elucidation of the etiologic diagno-
sis. Social context must always be taken into account.
We should always try to explain the clinical conditions
considering a single disease, but we need to recognize
the possibility of a second pathology.
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